Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Epigenetic silencing including histone modifications and DNA methylation is an important tumorigenic mechanism. However, its role in cancer immunopathology and immunotherapy is poorly understood. Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment. Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade and adoptive T-cell transfusion in tumour-bearing mice. Moreover, tumour EZH2 and DNMT1 are negatively associated with tumour-infiltrating CD8(+) T cells and patient outcome. Thus, epigenetic silencing of TH1-type chemokines is a novel immune-evasion mechanism of tumours. Selective epigenetic reprogramming alters the T-cell landscape in cancer and may enhance the clinical efficacy of cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epigenetic reprogramming with shRNAs targeting DNA methyltransferase 1 (DNMT1) or pan-DNMT blockers like decitabine and guadecitabine has been shown to resemble EZH2 inhibition in its capacity to promote CXCL9 and CXCL10 secretion in various models of breast, lung, and ovarian carcinoma”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [107]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The mTOR pathway has long been recognized to play a pivotal role in integrating signals at the cellular level and promote autoimmunity and carcinogenesis18,19.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“and TH1 cytokines”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Cited by
Items 601–700 of 1,000
Zhu, S., Wu, Q., Zhang, B., Wei, H., Li, B., Shi, W., Fang, M., Zhu, S., Wang, L., Zhou, Y. L., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106757 · Cited by 28
Hu, W., Wang, G., Yarmus, L. B., & Wan, Y. (2020) · Cancers · doi:10.3390/cancers12092496 · Cited by 24
“Such drugs, including DNA demethylating agents [81,82] and deacetylase inhibitors, are in clinical use against some leukemias and lymphomas.”
BackgroundEpigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials
Lai, P., & Wang, Y. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0216 · Cited by 27
Fan, T. T., Liu, Y., Liu, H., Wang, L., Tian, H., Zheng, Y., Zheng, B. J., Xue, L., Tan, F., Xue, Q., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02944-1 · Cited by 24
“The silence of Helper 1 (TH1)-type C-X-C motif chemokine ligand 9 (CXCL9) and C-X-C motif chemokine ligand 9 (CXCL10) promoted the therapeutic efficacy of PD-L1 checkpoint blockade by reshaping effector T cell tumor infiltration [16].”
BackgroundRKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity
Touboul, R., Baritaki, S., Zaravinos, A., & Bonavida, B. (2021) · Cancers · doi:10.3390/cancers13246247 · Cited by 25
The immune subtypes and landscape of sarcomas
Weng, W., Yu, L., Li, Z., Tan, C., Lv, J., Lao, I. W., Hu, W., Deng, Z., Liu, Z., Wang, J., et al. (2022) · BMC Immunology · doi:10.1186/s12865-022-00522-3 · Cited by 25
“Therapeutic strategies such as demethylating agents [49], chemo-/radiotherapy inducing immunogenic cell death (ICD) [50], and tumor vaccines [51] might induce immune infiltration to reinvigorate the immune system in these patients.”
BackgroundPD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?
Zwergel, C., Fioravanti, R., & Mai, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103435 · Cited by 24
Zhang, Y., Chen, J., Liu, H., Mi, R., Huang, R., Li, X., Fei, F., Xie, X., & Ding, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1099892 · Cited by 26
Peng, Z.-P., Liu, X.-C., Ruan, Y.-H., Jiang, D., Huang, A.-Q., Ning, W.-R., Jiang, Z.-Z., Zheng, L., & Wu, Y. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005986 · Cited by 25
“It has been reported that CXCL10 expression was negatively regulated by H3K27me3, 18 whose methylation depended on the methyl groups provided by S- adenosyl-methionine (SAM) downstream of 1C metabolism.”
Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors
Kim, D. J., Anandh, S., Null, J. L., Przanowski, P., Bhatnagar, S., Kumar, P., Shelton, S. E., Grundy, E. E., Chiappinelli, K. B., Kamm, R. D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37807-z · Cited by 27
“DNA hypomethylating agents such as 5-Azacytidine (5-Aza) thatinhibit DNMT1 were previously shown to potentiate the expression of Th1 chemokines that are important for CTL entry into tumors 4 .”
Zhao, L., Chen, X., Wu, H., He, Q., Ding, L., & Yang, B. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115724 · Cited by 26
Self-citationDNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire
Nie, J., Zhang, Y., Li, X., Chen, M., Liu, C., & Han, W. (2016) · Oncotarget · doi:10.18632/oncotarget.9352 · Cited by 24
“The epigenetic modifying agents were recently reported to induce the expression of Th1-type chemokines and promote effector T cell trafficking to the tumor environment [34].”
BackgroundLoveridge, C. J., Mui, E. J., Patel, R., Tan, E. H., Ahmad, I., Welsh, M., Galbraith, J., Hedley, A., Nixon, C., Blyth, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2565 · Cited by 27
“Similarly, epigenetic silencing of CXCL9 and CXCL10 appeared to promote tumor immune-evasion in ovarian cancer (47).”
BackgroundHuman Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis
Crespo, J., Wu, K., Li, W., Kryczek, I., Maj, T., Vatan, L., Wei, S., Opipari, A. W., & Zou, W. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700755 · Cited by 28
Self-citationLiu, Z.-L., Liu, J., Staiculescu, D., & Chen, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018026 · Cited by 27
Takata, K., Chong, L. C., Ennishi, D., Aoki, T., Li, M. Y., Thakur, A., Healy, S., Viganò, E., Dao, T., Kwon, D., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci145343 · Cited by 26
“demonstrated multiple EZH2mediated effects on the TME, such as increasing levels of the Th1 type chemokines, CXCL9 and CXCL10 (38).”
BackgroundHDAC Inhibitors with PD-1 Blockade: A Promising Strategy for Treatment of Multiple Cancer Types?
Beg, A. A., & Gray, J. E. (2016) · Epigenomics · doi:10.2217/epi-2016-0066 · Cited by 24
Getting the right combination to break the epigenetic code
Tolu, S. S., Viny, A. D., Amengual, J. E., Pro, B., & Bates, S. E. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00972-1 · Cited by 30
“…phase II trial involving patients with irinotecan-refractory metastatic colorectal cancer did not demonstrate improved PFS and OS with the DNMT inhibitor guadecitabine plus irinotecan versus standard-of-care regorafenib or TAS-102, despite promising preclinical data supporting the combination 87 .”
Liu, K., Li, Y., Shen, M., Xu, W., Wu, S., Yang, X., Zhang, B., & Lin, N. (2025) · Biomolecules · doi:10.3390/biom15010071 · Cited by 28
“As discussed earlier, the study led by Peng et al. revealed that combined EZH2 inhibition with DNA methylation inhibition elicits the secretion of Th1-type chemokines in tumors, amplifying the immune response against cancer [131].”
InfluentialCombinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
Al-Saafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546717 · Cited by 27
“…inhibitors are capable to reverse the epigenetic silencing of T helper 1 immunostimulatory chemokines including CXCL9 and CXCL10 and, in turn, promote T cell traf fi cking to the TME and enhance the sensitivity to immunotherapeutic agents such as ICIs and adoptive T cell transfer (9).”
Huang, C., Gao, Y., Chen, J., Hong, J. H., Jiang, Y., Chai, K. X. Y., Li, Y., Wang, P., Wang, Y., Gao, J., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0587 · Cited by 31
Reticker-Flynn, N. E., & Engleman, E. G. (2020) · eLife · doi:10.7554/elife.53839 · Cited by 26
Integrated Genomic Characterization of the Human Immunome in Cancer
Li, Y., Triplett, T., Burgman, B., Sun, M., McGrail, D. J., Qi, D., Shukla, S., Wu, E., Wu, C. J., Capasso, A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0384 · Cited by 28
“2), neoantigen burden (3), PD-L1 or PD-L2 mRNA expression (4), epigenetic markers, and immune cell infiltration profiles (5).”
BackgroundMondello, P., Ansell, S. M., & Nowakowski, G. S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.826594 · Cited by 25
“Furthermore, EZH2 mutation represses CIITA, which is master regulator of MHC class II, NLRC5, which is a transactivator of MHC class I, and Th1-type chemokines (Peng et al., 2015).”
BackgroundDong, P., Zhang, X., Peng, Y., Zhang, Y., Liu, R., Li, Y., Pan, Q., Wei, W., Guo, S., Zhang, Z., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1279 · Cited by 26
Self-citationZhang, X., Huo, X., Guo, H., & Xue, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.965244 · Cited by 28
“infiltration in the tumor microenvironment (Peng et al., 2015), which hurdles the effect of PARP inhibitors.”
BackgroundGong, Q., Guo, Z., Sun, W., Du, X., Jiang, Y., & Liu, F. (2022) · BMC Cancer · doi:10.1186/s12885-022-10302-2 · Cited by 25
“Studies have shown that evolutionary pressure can influence tumorigenesis by acting on the cellular genome through a series of epigenetic mechanisms [31, 32].”
BackgroundHuang, Y., Chen, Z., Shen, G., Fang, S., Zheng, J., Chi, Z., Zhang, Y., Zou, Y., Gan, Q., Liao, C., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2318815 · Cited by 24
Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
Re, V. D., Caggiari, L., Repetto, O., Mussolin, L., & Mascarin, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101596 · Cited by 25
“Indeed, mutations negatively affecting the antigen processing, antigen presentation and recognition, or immune cell migration, may lead to a malfunctioned immunity [41,42].”
BackgroundDevelopment of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy
Lugassy, J., Abdala-Saleh, N., Jarrous, G., Turky, A., Saidemberg, D., Ridner-Bahar, G., Berger, N., Bar-On, D., Taura, T., Wilson, D. S., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2501791122 · Cited by 25
“This includes the induction of CXCL10 via an epigenetic approach ( 15 ).”
Yang, D. D., Macmorland, W., & Arnold, J. N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643941 · Cited by 30
Calmeiro, J., Carrascal, M. A., Tavares, A. R., Ferreira, D. A., Gomes, C. M. F., Cruz, M. T., Falcão, A. C., & Neves, B. M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105309 · Cited by 22
Natural killer cell therapy: A new frontier for obesity-associated cancer
Mylod, E., Lysaght, J., & Conroy, M. J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215620 · Cited by 22
Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer
Sun, Q., Wei, X., Wang, Z., Zhu, Y. Y., Zhao, W., & Dong, Y. (2022) · Cancers · doi:10.3390/cancers14143294 · Cited by 24
“Further, epigenetic modulators alleviated the repression and promoted efficacy of anti-PDL1 inhibitors [26].”
BackgroundSeyhan, A. A., & Carini, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010041 · Cited by 24
Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
Li, C., Wang, Z., Yao, L., Lin, X., Jian, Y., Li, Y., Zhang, J., Shao, J., Tran, P. D., Hagman, J. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46422-5 · Cited by 24
“To further identify how Mi-2 β regulates ISGs expression, liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed to identify co-factors of Mi-2 β protein.”
InfluentialFischetti, I., Botti, L., Sulsenti, R., Cancila, V., Enriquez, C., Ferri, R., Bregni, M., Crivelli, F., Tripodo, C., Colombo, M. P., et al. (2024) · Epigenomics · doi:10.2217/epi-2023-0374 · Cited by 24
“Furthermore, the 30 mg / Kg dosage was also used in the paper by Peng et al. [21] , which showed that the combination of GSK-126 and a second epigenetic modulator (the DNMT inhibitor 5-AZA-dC) synergized with adoptive T cell transfer, causing increased tumor T cell infiltration, production of…”
BackgroundMethodDrug discovery and therapeutic delivery for the treatment of B and T cell tumors
Stephenson, R. E., & Singh, A. K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.010 · Cited by 25
Phenotype and tissue distribution of CD28H+immune cell subsets
Crespo, J., Vatan, L., Maj, T., Liu, R., Kryczek, I., & Zou, W. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1362529 · Cited by 22
“Single-cell suspensions from tissue were stained for extracellular surface antigens with specific antibodies, followed by fixation and permeabilization using Perm/Fix solution (ThermoFischer), then stained against intracellular antigens as described.(14,15) Viable single cells were analyzed.”
MethodSelf-citationPrognostic and predictive values of CXCL10 in colorectal cancer
Chen, J., Chen, Q.-L., Wang, W.-H., Chen, X., Hu, X., Liang, Z., Cao, Y., Cao, Y., & Su, S.-B. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02299-6 · Cited by 24
“Moreover, it has been found that epigenetic silencing of TH1-type chemokines, such as CXCL9 and CXCL10, shapes tumor immunity and immunotherapy [57].”
BackgroundSelf-citationThe follicular lymphoma epigenome regulates its microenvironment
Amin, R., & Braza, M. S. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02234-9 · Cited by 27
Qiu, Z., Ji, J., Xu, Y., Zhu, Y., Gao, C., Wang, G., Li, C., Zhang, Y., Zhao, J., Wang, C., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02197-w · Cited by 24
Migratory Engineering of T Cells for Cancer Therapy
Michaelides, S., Obeck, H., Kechur, D., Endres, S., & Kobold, S. (2022) · Vaccines · doi:10.3390/vaccines10111845 · Cited by 21
“Recent discoveries reveal several mechanisms, such as epigenetic silencing of CCL5, CXCL9, and CXCL10 in different tumor entities [52,74] or post-translational cleavage of those same chemokines by enzymes such as dipeptidylpeptidase 4 or matrix metalloprotease-9 [75–77].”
BackgroundChen, L., Xu, X.-Y., Zhong, X.-D., Liu, Y., Zhu, M.-H., Tao, F., Li, C.-Y., She, Q. S., Yang, G.-J., & Chen, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106409 · Cited by 23
Targeting the crosstalk of epigenetic modifications and immune evasion in nasopharyngeal cancer
Looi, C.-K., Foong, L. C., Chung, F. F., Khoo, A. S. B., Loo, E.-M., Leong, C., & Mai, C. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09830-9 · Cited by 24
“Thus, studies testing the effect of epigenetic modulating agents have shed light on their potential utility in reversing this repression (Peng et al. 2015).”
BackgroundChromatin Remodelers Are Regulators of the Tumor Immune Microenvironment
Chaudhri, A., Lizee, G. A., Hwu, P., & Rai, K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2244 · Cited by 23
Role of chemokines in aging and age-related diseases
Chaudhary, J. K., Danga, A. K., Kumari, A., Bhardwaj, A., & Rath, P. C. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.112009 · Cited by 30
The tumor microenvironment disarms CD8+ T lymphocyte function via a miR-26a-EZH2 axis
Long, H., Xiang, T., Luo, J., Li, F., Lin, R., Liu, S.-Q., Jiang, S., Hu, C., Chen, G., Wong, E., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1245267 · Cited by 23
“Ovarian cancer cells employ the EZH2 machinery to suppress expression of the chemokines CXCL9 and CXCL10, which thereby serves as a prominent mechanism to exclude T helper type 1 (Th1) cells from the tumor.(21) Unexpectedly however, in CTLs, EZH2 was identified as an essential gene activator for promoting effector fun…”
BackgroundChallenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders
Phillips, T. J., Devata, S., & Wilcox, R. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0201-6 · Cited by 21
“However, treatment with a hypomethylating agent reversed this epigenetic silencing, increased migration of effector T cells to the tumor site, and significantly improved the efficacy of CPB [82].”
BackgroundTheranostic nanomedicine by surface nanopore engineering
Li, Z., Yu, L., Yang, T., & Chen, Y. (2018) · Science China Chemistry · doi:10.1007/s11426-018-9297-5 · Cited by 21
The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
Zhylko, A., Winiarska, M., & Graczyk‐Jarzynka, A. (2020) · Cancers · doi:10.3390/cancers12082030 · Cited by 22
“Exhausted central memory T cells have a distinct transcriptional status compared to healthy ones [140,141].”
BackgroundKaito, S., & Iwama, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010074 · Cited by 21
“Mechanistically, it has been proposed that EZH2-mediated gene silencing of chemokines, such as CXCL9 and CXCL10, prevents effector T-cell trafficking to the tumor microenvironment, thereby allowing tumor cells to evade immunity [101].”
BackgroundZhu, X., Zhao, L., & Lang, J. (2018) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001334 · Cited by 20
Self-citationCancer germline antigens and tumor-agnostic CD8+ T cell evasion
Kortleve, D., Coelho, R. M. L., Hammerl, D., & Debets, R. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.03.006 · Cited by 20
Kano, N., Ong, G. H., Ori, D., & Kawai, T. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.910654 · Cited by 21
Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer
Shin, D. S., Park, K., Garon, E. B., & Dubinett, S. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.005 · Cited by 20
Targeting epigenetic regulation for cancer therapy using small molecule inhibitors
Kumar, A., Emdad, L., Fisher, P. B., & Das, S. K. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.01.001 · Cited by 20
Dang, Y., Xiao-Jiao, C. H. E. N., Yu, J., Shu-Hong, Z. H. A. O., Cao, X., & Qing, W. A. N. G. (2023) · Neoplasma · doi:10.4149/neo_2023_220726n757 · Cited by 22
Yi, X.-F., Gao, R.-L., Sun, L., Wu, Z.-X., Zhang, S., Huang, L., Han, C., & Ma, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114770 · Cited by 25
Jiang, C. Y., Zhao, L., Green, M. D., Ravishankar, S., Towlerton, A. M. H., Scott, A. J., Raghavan, M., Cusick, M. F., Warren, E. H., & Ramnath, N. (2024) · Scientific Reports · doi:10.1038/s41598-023-48546-y · Cited by 23
“Preclinical and translational studies have identified primary and acquired mechanisms of resistance 44 including hepatic siphoning 45 , tumoral loss of HLA Class I 46 , T cell chemokine silencing 47 , and immunometabolic checkpoints 48 .”
BackgroundSelf-citationEpigenetic control of immunoevasion in cancer stem cells
Galassi, C., Esteller, M., Vitale, I., & Galluzzi, L. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.08.004 · Cited by 22
Wu, Y., Yuan, L., Lu, Q., Xu, H., & He, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.7771 · Cited by 25
“Treatment with epigenetic modulators such as EZH2 inhibitor removes the repression and increases effector T cell tumor infiltration, slows down tumor progression, and improves the therapeutic efficacy of programmed death‐ligand 1 (PD‐L1; also termed B7‐H1) checkpoint blockade and adoptive T cell transfusion in tumor‐b…”
Zhu, C., Zhai, T., Su, M., Pan, H., Tang, Q., Huang, B., Chi, X.-R., Li, N., Xie, L.-H., Qiu, S.-Q., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-07341-9 · Cited by 22
“However, the percentage of both pDC and tDC was higher in VEGFC-high group than VEGFC-low group.”
Chen, J., Sun, H.-W., Wang, R.-Z., Zhang, Y., Li, W., Wang, Y.-K., Wang, H., Jia, M., Xu, Q., Zhuang, H., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2497172 · Cited by 23
“51,52 Here, we demonstrated that glutamate significantly suppressed the expression of EZH2 but it did not exert an impact on other methylation enzymes and siEZH2 effectively mimicked glutamate-induced CCL2 expression.”
RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications
Huang, S., Li, Z., Lin, W., Xie, R., & Huang, H. (2025) · MedComm · doi:10.1002/mco2.70322 · Cited by 22
“Within the TME, EZH2 suppresses the production of the Th1-type chemokine CXCL9 [73], reducing CD8 + T cell infiltration.”
EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy
Gu, Y., He, H., Qiao, S., Shao, Y., Wang, L., Zhang, Z., Zhang, L., & Zhou, F. (2025) · Advanced Science · doi:10.1002/advs.202505785 · Cited by 25
Epigenetic Drugs and Their Immune Modulating Potential in Cancers
Liang, Y., & Turcan, Ş. (2022) · Biomedicines · doi:10.3390/biomedicines10020211 · Cited by 21
“the number of tumor infiltrating CD8+ lymphocytes and prognosis in an ovarian cancer model, and that epigenetic silencing of the chemokines CXCL9 and CXCL10 resulted in immunosuppression [65].”
BackgroundNanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival
Urbanova, M., Cihova, M., Buociková, V., Slopovský, J., Dubovan, P., Pinďák, D., Tomáš, M., García‐Bermejo, L., Rodríguez-Garrote, M., Earl, J., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115179 · Cited by 20
Epigenetic modulations of immune cells: from normal development to tumor progression
Xu, Y., He, Z., Du, J., Chen, K., Creemers, J. W. M., Wang, B., Fan, L., & Wang, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.88327 · Cited by 23
“In a human ovarian cancer model, H3K27me3 mediated by EZH2 at their promoter regions represses the tumor production of Th1-associated chemokines like CXCL10, which influences tumor progression by mediating recruitment of effector T cells to TME (115).”
BackgroundThe next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer
Ding, K., Mou, P., Wang, Z., Liu, S., Liu, J., Lü, H., & Yu, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298524 · Cited by 25
“Various approaches are being explored to modify the TME and increase T cell in fi ltration, thereby transforming tumors from an immune “ cold ” state to an immune “ hot ” state through various mechanisms (128).”
BackgroundIbrahim, M. L., Zheng, H., Barlow, M. L., Latif, Y., Chen, Z., Yu, X., & Beg, A. A. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300475 · Cited by 22
McGoverne, I., Dunn, J., Batham, J., Tu, W. J., Chrisp, J. S., & Rao, S. (2020) · BMC Immunology · doi:10.1186/s12865-020-00353-0 · Cited by 19
Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms
Chen, J., Zhang, H., Zhou, L., Hu, Y., Li, M., He, Y., & Li, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.584367 · Cited by 21
“The finding indicates that there exists a negative association between tumor-infiltrating CD8 T cells and epigenetic silencing (27).”
BackgroundCXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer
Nie, S., Wan, Y., Wang, H., Liu, J., Yang, J., Sun, R., Meng, H., Ma, X., Jiang, Y., & Cheng, W. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00864-3 · Cited by 19
Huang, L., Yi, X., Yu, X., Wang, Y., Zhang, C., Qin, L., Guo, D., Zhou, S., Zhang, G., Deng, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.762023 · Cited by 19
“Small molecules can also epigenetically convert cold tumors to hot tumors by altering the gene expression of TH1 chemokines (50).”
BackgroundInhibiting DNA methylation improves antitumor immunity in ovarian cancer
Chiappinelli, K. B., & Baylin, S. B. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160186 · Cited by 22
Merle, M., Fischbacher, D., Liepert, A., Grabrucker, C., Kroell, T., Kremser, A., Dreyßig, J., Freudenreich, M., Schuster, F. R., Borkhardt, A., et al. (2019) · Immunological Investigations · doi:10.1080/08820139.2019.1661429 · Cited by 20
“As CXCL9- and CXCL10-mediated tumor infiltration by T-cells is suppressed due to DNA-methylation of the encoding genes, treatment with epigenetic modulating drugs can increase chemokine release and subsequently also effector T cell tumor-infiltration (Peng et al. 2015).”
BackgroundPace, L. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a037754 · Cited by 20
Chen, J.-S., Hsieh, Y.-C., Chou, C.-H., Wu, Y., Yang, M.-H., Chu, S.-H., Chao, Y.-S., & Chen, C.-N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810677 · Cited by 19
“This finding was consistent with a previous study on epigenetic modulation via DNA methyltransferase and HDACis that rationally sensitized tumors to anti-PD1/PD-L1 antibody therapy [49].”
ResultWang, S., Huang, M., Chen, M., Sun, Z., Jiao, Y., Ye, G., Pan, J., Ye, W., Zhao, J., & Zhang, D. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006381 · Cited by 21
Roles of cGAS-STING Pathway in Radiotherapy Combined with Immunotherapy for Hepatocellular Carcinoma
Ma, J., Xin, Y., Wang, Q., & Ding, L. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0373 · Cited by 19
Exosomes as a Therapeutic Strategy in Cancer: Potential Roles as Drug Carriers and Immune Modulators
Abedi, A., Moghaddam, M. M., Kachuei, R., & Fooladi, A. A. I. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189238 · Cited by 22
Causes, effects, and clinical implications of perturbed patterns within the cancer epigenome
Oleksiewicz, U., & Machnik, M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.014 · Cited by 19
Reid, B. M., Vyas, S., Chen, Z., Chen, A., Kanetsky, P. A., Permuth, J. B., Sellers, T. A., & Saglam, O. (2021) · BMC Cancer · doi:10.1186/s12885-021-08413-3 · Cited by 18
“kines, CXCL9 and CXCL10, resulting in reduced T-cell recruitment to the tumor microenvironment [41].”
BackgroundLedys, F., Kalfeist, L., Galland, L., Limagne, E., & Ladoire, S. (2021) · Cancers · doi:10.3390/cancers13235999 · Cited by 21
Roalsø, M. T. T., Hald, Ø. H., Alexeeva, M., & Søreide, K. (2022) · Cancers · doi:10.3390/cancers14030546 · Cited by 18
Xu, M., Chang, J., Wang, W., Wang, X., Wang, X., Weng, W., Tan, C., Zhang, M., Ni, S., Wang, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.934083 · Cited by 20
“For IS2, the absence of immune cell infiltration consequently represents a noninflamed TME and so therapeutic strategies that induce immune infiltration may be useful to reinvigorate the immune system in these patients, such as demethylating agents (59), chemo/radiotherapy-inducing immunogenic cell death (60), and tum…”
BackgroundSelf-citationSylvestre, M., Tarte, K., & Roulois, D. (2019) · Epigenomics · doi:10.2217/epi-2019-0165 · Cited by 19
Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review
Lee, Y.-T., Chuang, Y., & Chan, M. W. Y. (2020) · Epigenomes · doi:10.3390/epigenomes4040027 · Cited by 18
“Treatment with EZH2i or DNMTi reactivates these chemokines and allows effector T-cell tumor trafficking in the tumor microenvironment [88].”
BackgroundTumor immunotherapy—the potential of epigenetic drugs to overcome resistance
Grunewald, C. M., Schulz, W. A., Skowron, M. A., Hoffmann, M. J., & Niegisch, G. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.06.24 · Cited by 19
A novel aptamer-based small RNA delivery platform and its application to cancer therapy
Tanno, T., Zhang, P., Bailey, C. M., Wang, Y., Ittiprasert, W., Devenport, M., Zheng, P., & Liu, Y. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.004 · Cited by 18
“Moreover, Ezh2-mediated histone modification has known to repress the expression of Cxcl9 in cancer cells, and subsequently decrease effector T-cell trafficking into tumor sites.(23,50) Since Ezh2 is one of the miR-26a target genes, restoration of miR-26a in cancer cells by cancer-specific miR-26a delivery provided a…”
BackgroundEpigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
Kawakubo, K., Castillo, C. F.-D., & Liss, A. S. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01915-2 · Cited by 18
“EZH2 is also associated with silencing of TH-1 type chemokines, including CXCL9 and CXCL10 [91].”
BackgroundThe pleiotropic roles of EZH2 in T-cell immunity and immunotherapy
Wang, Y., Bui, T., & Zhang, Y. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03466-x · Cited by 19
“Tumor EZH2 is also reported to repress ovarian cancer cell production of chemokines CXCL9 and CXCL10, reducing effector T-cell trafficking to the tumor environment [80].”
BackgroundTurbulence of glutamine metabolism in pan-cancer prognosis and immune microenvironment
He, S., Zhang, S., Yao, Y., Xu, B., Niu, Z., Liao, F., Wu, J., Song, Q., Li, M., & Liu, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1064127 · Cited by 18
“In addition to DCs, the other immune cells like Th1 cells, which recruit and activate macrophages and cytotoxic T cells mainly by expressing CD40L and cytokines like INFG and IL-2, also elevated in GMscore-high group (58).”
BackgroundCombining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects
Huang, R., Wu, Y., & Zou, Z. (2022) · Epigenomics · doi:10.2217/epi-2022-0320 · Cited by 19
Regulation of main ncRNAs by polyphenols: A novel anticancer therapeutic approach
Zhang, L., Kang, Q., Kang, M., Jiang, S., Yang, F. W., Gong, J., Ou, G., & Wang, S. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155072 · Cited by 19
Wang, M., Yu, F., & Li, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1268745 · Cited by 22
Zhao, X., Liu, B., William, W. N., Tsanov, K. M., Ho, Y.-J., Barriga, F. M., Lim, R. J., Trifas, M., Khandekar, A., Du, Y., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.12.020 · Cited by 20
The immune checkpoint regulator CD40 potentiates myocardial inflammation
Jiménez, J., Amrute, J., Ma, P., Wang, X., Das, S., Dai, R., Komaru, Y., Herrlich, A., Mack, M., & Lavine, K. J. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00633-1 · Cited by 22
Tackling drug resistance in ovarian cancer with epigenetic targeted drugs
Zhao, L., Guo, H., Chen, X., Zhang, W., He, Q., Ding, L., & Yang, B. W. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175071 · Cited by 17
Self-citation
Metadata
- Authors
- Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., Kotarski, J., Tarkowski, R., Dou, Y., Cho, K., Hensley-Alford, S., Munkarah, A., Liu, R., & Zou, W.
- Affiliations
- University of Michigan (US)
- Medical University of Lublin (PL)
- Henry Ford Health (US)
- Corresponding author
- Zou, Weiping
- ORCID
- Venue
- Nature
- Published
- 2015-10-26
- Volume
- 527
- Issue
- 7577
- Pages
- 249-253
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4779053
- OpenAlex
- W2103021272
- Cited by
- 1,201
- References
- 37
- Citations by year
- 2026: 79 · 2025: 100 · 2024: 104 · 2023: 132 · 2022: 155 · 2021: 159 · 2020: 125 · 2019: 109 · 2018: 85 · 2017: 89 · 2016: 61 · 2015: 2
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (CA099985, R01CA123088, R01CA152470, CA193136, R01CA156685, CA123088, 5P30 CA 46592, CA156685, CA152470, R01CA171306, R01CA193136, CA171306, R01CA099985, F31CA189440, R01CA190176, CA190176, P30CA046592)
- National Institute of General Medical Sciences (R01GM082856)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- epigenetic silencing, EZH2, DNMT1, CXCL9, CXCL10, ovarian cancer, tumor immunosuppression, adoptive T cell therapy, CD8+ T cells, H3K27me3, DNA methylation, histone modifications, tumor microenvironment, immunotherapy response
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, DNA (Cytosine-5-)-Methyltransferase 1, Animals, DNA (Cytosine-5-)-Methyltransferases, Female, Histones, Humans, Immunotherapy, Lysine, Ovarian Neoplasms, Prognosis, Tumor Cells, Cultured, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Th1 Cells, Chemokines, Tumor Escape, DNA Methylation, Gene Silencing, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Mice, Chemokine CXCL10, Chemokine CXCL9, B7-H1 Antigen, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.